Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants enrolled in a Phase 1 clinical trial, marking one of the strongest early signals for a genetic approach to cardiovascular disease. The investigational therapy, which uses CRISPR-based editing, targets the PCSK9 gene — a well-validated regulator of LDL cholesterol.
The Phase 1 study enrolled a small cohort of patients with elevated cholesterol, assessing safety and tolerability alongside efficacy. The 62% reduction, seen at the highest dose, was sustained over the follow-up period, though durability data remain limited. No serious adverse events were reported, though a full safety profile has not yet been published.
Lilly has not disclosed the regulatory pathway for this candidate, but the company is known to be expanding its genetic medicine pipeline. Three new Lilly deals — announced alongside these data — suggest a broader push into gene editing and delivery technologies. An FDA filing is likely at least several quarters away, pending larger dose-ranging and durability studies.
The results sent positive ripples through biotech markets, reinforcing Lilly's position in cardiovascular gene therapy. The global PCSK9 inhibitor market, dominated by injectable monoclonal antibodies, exceeds $2 billion annually; a one-time gene-editing treatment could capture significant share if safety and durability hold up in larger trials.
However, the therapy is still early-stage — Phase 1 data from a small cohort may not translate to broader populations. Long-term risks of off-target editing and immune responses to the delivery vector remain unresolved. As one analyst noted, single-digit percentage reductions in cholesterol can still leave patients at risk; a 62% cut, while dramatic, will need to be confirmed in hundreds of patients before any regulatory conclusion is drawn.